Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus.

Abstract

BACKGROUND:

Type 1 diabetes mellitus is associated with acute and long-term complications, to which pre- and postprandial hyperglycemia are independent contributors. The objective of this review was to evaluate evidence-based information using biphasic insulin aspart 30 in the treatment of type 1 diabetes mellitus.

METHODS:

The study reviewed the Cochrane Database and scientific literature (PubMed) published until January 2008 using the words biphasic insulin aspart 30 insulin or premixed aspart insulin.

CONCLUSIONS:

Biphasic insulin aspart 30 is similar in efficacy to biphasic human insulin in improving hemoglobin A(1c) levels, with the advantage of a better postprandial glucose profile.

EXPERT OPINION:

There is evidence supporting the efficacy and safety of biphasic insulin aspart 30 insulin. However, the need for well-designed clinical trials aimed at understanding the potential differences in safety and efficacy between patients with type 1 and type 2 diabetes is crucial.

• Authors: Pedro A Velásquez-Mieyer, Claudia P Neira
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 9 Issue 13 Pg. 2377-82 (Sep 2008) ISSN: 1744-7666 [Electronic] England
• PMID: 18710361 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Biphasic Insulins
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Insulin
• insulin aspart, insulin aspart protamine drug combination 30:70
• Insulin, Isophane
• Insulin Aspart

Topics

• Biphasic Insulins
• Diabetes Mellitus, Type 1 (drug therapy)
• Glycated Hemoglobin (analysis)
• Humans
• Hypoglycemic Agents (adverse effects, pharmacokinetics, therapeutic use)
• Insulin (adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)
• Insulin Aspart
• Insulin, Isophane
• Randomized Controlled Trials as Topic